Medscape is available in 5 Language Editions – Choose your Edition here.


Paraneoplastic Syndromes

  • Author: Luigi Santacroce, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
Updated: Sep 30, 2015


Paraneoplastic syndromes are rare disorders that are triggered by an altered immune system response to a neoplasm. They are defined as clinical syndromes involving nonmetastatic systemic effects that accompany malignant disease.[1, 2, 99]

In a broad sense, these syndromes are collections of symptoms that result from substances produced by the tumor, and they occur remotely from the tumor itself. The symptoms may be endocrine,[3] neuromuscular or musculoskeletal, cardiovascular, cutaneous, hematologic, gastrointestinal, renal, or miscellaneous in nature.

Although fever is the most common presentation, several clinical pictures may be observed, each of which specifically simulates more common benign conditions. These syndromes vary from dermatomyositis-polymyositis to Cushing syndrome[4] to the malignant carcinoid syndrome.

A large number of cancer patients show central nervous system (CNS) involvement.[5] The first report of a paraneoplastic syndrome has been attributed to a French physician, M. Auchè, who described peripheral nervous system involvement in cancer patients in 1890.[6]

Paraneoplastic syndromes may be the first or most prominent manifestation of a cancer. When a patient without a known cancer presents with one of the “typical” paraneoplastic syndromes, a diagnosis of cancer should be considered and investigated. Because of their protean manifestations, paraneoplastic syndromes should be managed by a coordinated team of physicians, including medical oncologists, surgeons, radiation oncologists, endocrinologists, hematologists, neurologists, and dermatologists.

For discussion of specific paraneoplastic syndromes, see the following Medscape Reference articles:

For patient education information, see the Cancer Center, as well as Brain Cancer, Bladder Cancer, and Breast Cancer.



The pathophysiology of paraneoplastic syndromes is complex and intriguing. When a tumor arises, the body may produce antibodies to fight it by binding to and destroying tumor cells. Unfortunately, in some cases, these antibodies cross-react with normal tissues and destroy them, which may result in a paraneoplastic disorder.[7] For example, antibodies or T cells directed against the tumor may mistakenly attack normal nerve cells. The detection of paraneoplastic anti-neural antibody was first reported in 1965.[8]

In other cases, paraneoplastic syndromes result from the production and release of physiologically active substances by the tumor. Tumors may produce hormones, hormone precursors, a variety of enzymes, or cytokines. Several cancers produce proteins that are physiologically expressed in utero by embryonic and fetal cells but not expressed by normal adult cells. These substances may serve as tumor markers (eg, carcinoembryonic antigen [CEA], alpha-fetoprotein [AFP], carbohydrate antigen 19-9 [CA 19-9]). More rarely, the tumor may interfere with normal metabolic pathways or steroid metabolism. Finally, some paraneoplastic syndromes are idiopathic.



The causes of the paraneoplastic syndromes associated with underlying cancers are not well known. Only a few cases clearly demonstrate an etiologic and a pathogenetic factor.

Miscellaneous syndromes

Fever is thought to result from the release of endogenous pyrogens (ie, lymphokines or tissue pyrogenes). Fever may also be related to necrotic-inflammatory phenomena of the tumor and/or to alterations in liver function and consequent disorders of steroidogenesis.

Dysgeusia seems to be related to alterations in the body's level of copper and zinc or to a morphofunctional variation of the tasting bodies (ie, gustative papillae).

Cachexia is thought to be caused by bioactive molecules produced by the tumor, such as alpha-lymphotoxin (tumor necrosis factor [TNF] alpha), peptides, and nucleotides, which are able to affect metabolism. Such modifications include an increase in the serum levels of fatty acids; a decrease in urea, alanine, and carbon dioxide; and alterations of glucose metabolism.

Rheumatologic syndromes

The causes of hypertrophic osteoarthropathy remain unknown, although several hypotheses have been developed (eg, estrogen or growth hormone [GH] production by the tumor, vagal hyperactivity).

The autoimmune basis of polymyositis and dermatomyositis is confirmed by the presence of a lymphoplasma cellular infiltrate of the muscular interstices and by the presence of muscle necrosis, which is revealed by increased serum levels of creatine kinase and lactic dehydrogenase (LDH) and an elevated erythrocyte sedimentation rate (ESR).

Onset of scleroderma and SLE could be related to production of antinuclear antibody (ANA), because antigens normally restricted to connective tissues are expressed aberrantly in cancer.

Renal syndromes

Secondary kidney amyloidosis and sedimentation of immunocomplexes in nephrons (and subsequent membranoproliferative glomerulonephritis) is thought to be the underlying mechanism of nephrotic syndrome and, frequently, neoplastic hypoalbuminemia, which is also related to reduced albumin synthesis.

Gastrointestinal syndromes

Gastrointestinal paraneoplastic disorders are related to production of molecules that affect the motility and secretory activity of the digestive tract, as follows:

  • Medullary thyroid carcinomas (MTCs) may produce several prostaglandins (PGs) (eg, PGE2 and PGF2) that lead to malabsorption and, consequently, unavailability of nutrients
  • Malignancies of the digestive system, especially those in the stomach or intestine, may lead to a protein-losing enteropathy resulting from tumor-mass inflammation and exudation

Hematologic syndromes

Erythrocytosis results from an increase of erythropoietin (EPO), which may occur in response to hypoxia, or may result from ectopic production of EPO or EPO-like substances or from altered catabolism of EPO itself. Erythrocytosis is common in cancers of the liver, kidney, adrenal glands, lung, thymus, and CNS as well as in gynecologic tumors and myosarcomas. It always disappears after removal of the primary tumor.

Anemia is a common presenting symptom of several neoplasms and results from chronic hemorrhages from ulcerated tumors, altered intestinal absorption of vitamins B-6 and B-12, and increased destruction or insufficient production of RBCs. Three types of paraneoplastic anemias may be described, as follows:

  • Chronic anemia resulting from an anti-erythropoietin factor, reduction in mean red blood cell (RBC) life, and poor iron availability
  • Microangiopathic hemolytic anemia resulting from diffuse intravascular coagulation (DIC), with formation of fibrin filaments in capillary vessels and consequent mechanical hemolysis
  • Autoimmune hemolytic anemia resulting from anti-RBC antibodies that can be either produced by lymphomatous clones or directed against novel antigens produced by teratomas and ovarian cystadenocarcinomas
  • DIC is typical of epithelial tumors, leukemias, and lymphomas (in particular, acute promyelocytic leukemia); usually, DIC has a slow and gradual onset, but in some cases, DIC appears in an acute and severe form, characterized by typical thrombotic and/or hemorrhagic manifestations, and sometimes leading to thrombocytopenia
  • Thrombocytopenia may also be caused by autoantibodies; the causes of thrombocytosis are still unknown
  • Marantic endocarditis is typical of mucous adenocarcinomas of lung, stomach, and pancreas
  • Leukemoid reactions are probably caused by mechanical stimulation of bone marrow, resulting from bone metastases, or they may be caused by humoral stimuli resulting from neosynthesized blastic factors or factors released from the foci of tumor necrosis
  • Leukopenia is not common and is essentially related to metastatic compression of bone marrow
  • Gammopathies occurring in cancer patients may be monoclonal (immunoglobulin G [IgG] or the rarer immunoglobulin M [IgM]), monoclonal secondary (IgG + IgM), or polyclonal (IgG); gammopathies probably are related to an antigenic stimulus of the tumor on some immune clones

Cutaneous syndromes

Causes of cutaneous paraneoplastic syndromes are as follows:

  • Itching results from hypereosinophilia and is typical of Hodgkin lymphoma, in which it has specific diagnostic and prognostic significance [9]
  • Immune system depression, which may be observed in most patients with cancer, is often responsible for the reactivation of latent varicella-zoster virus (VZV) in the sensory ganglia and subsequent attacks of herpes zoster
  • Pancreatic tumors can release several lipases and lithic enzymes into the bloodstream, leading to adipose nodular necrosis of subcutaneous tissues; this condition is characterized by painful pink to dark-reddish nodules under the skin; these nodules often ulcerate, causing leakage of an oily material
  • Flushes can be observed in patients with acute leukemias, mastocytosis, carcinoids, medullary thyroid cancer, or pancreatic carcinomas that secrete vasoactive substances, mainly prostaglandins (alpha, E1, E2, F2, I2)
  • Dermic melanosis results from melanin precursors that enter the bloodstream and, because they cannot be eliminated completely via urine, accumulate in the dermis, which results in a peculiar grey to black-bluish color of the overlying skin

Endocrine syndromes

The pathogenesis of paraneoplastic endocrine syndromes results from aberrant production by tumors of protein hormones, hormone precursors, or hormonelike substances. Cancers generally do not synthesize steroid hormones, except those arising in organs with physiological steroidogenesis (ie, gonads or adrenals).

Neurologic/neuromuscular syndromes

The pathogenesis of neuromuscular paraneoplastic disorders is unknown, but they probably are multifactorial, correlated with a virus becoming virulent, autoantibody formation, or production of substances that alter nervous functions.[100]

The muscular system is involved in myasthenic phenomena (on a toxic and metabolic basis) that can be either simple (affecting the pelvic girdle) or part of Eaton-Lambert myasthenic syndrome (ELMS). According to some recent reports, ELMS may be related to production of tumor proteins that may provoke production of anti–calcium-channel antibodies.

Autoantibodies directed against the central neurons and brain often are present in the serum and cerebrospinal fluid (CSF) of patients with sensory and mixed neuropathies. CSF analysis may reveal increased albumin and immunoglobulins. Patients with mixed neuropathy usually show a distal nervous demyelination, while patients with sensory neuropathy have ganglionic degeneration.

Patients with subacute necrotic myelitis show a characteristic extended necrosis of the spinal cord, while those with the more rare subacute myelitis have characteristic degeneration of the anterior horns of the spinal cord, which sometimes extends to the brain. Both types of myelitis probably have a toxic origin.

Patients with cerebellar paraneoplastic disorders usually have degenerative loss of the molecular, granular, and Purkinje layers of the cerebellar cortex. Sometimes a loss of neurons of the spinocerebellar tract and of the posterior cords of the spinal cord can occur. Elevation of CSF albumin and lymphocyte levels is usually observed in these patients.

Individuals with paraneoplastic encephalitis commonly have lymphocytic infiltration of the medial sections of the temporal lobes, with a loss of neurons.

Patients with involvement of the semioval center have an acute and ill-defined onset of disease. This condition is often called progressive multifactorial leukoencephalopathy and is related to the site of the nervous injury. This condition probably has a viral origin, resulting from the action of two papovaviruses, JV and an SV-40–like virus, both of which have been isolated in the brains of some patients. Some areas of demyelination that tend to be confluent and that spare central axons can be demonstrated by histologic examination.



The reported frequency of paraneoplastic syndromes ranges from 10-15% to 2-20% of malignancies, However, these could be underestimates. Neurological paraneoplastic syndromes are estimated to occur in fewer than 1% of patients with cancer. Similarly, the true incidence of deaths and complications related to paraneoplastic syndromes is unknown.

No race predilection for paraneoplastic syndromes is reported. No sex predilection is known. People of all ages may be affected by cancers and their related paraneoplastic syndromes.



Because paraneoplastic syndromes differ widely from individual to individual, prognosis may vary greatly. For example, disseminated intravascular coagulation indicates a poor prognosis, whereas hypertrophic osteoarthropathy is one of the few paraneoplastic syndromes that may indicate a more favorable prognosis. Some paraneoplastic disorders may resolve spontaneously.

Death may result from the underlying cancer or from an irreversible system impairment, usually acute heart failure or kidney failure. In a review of patients with paraneoplastic pemphigus, infection was a major cause of death.[10]

Contributor Information and Disclosures

Luigi Santacroce, MD Assistant Professor, Medical School, State University at Bari, Italy

Disclosure: Nothing to disclose.


Lodovico Balducci, MD Professor, Oncology Fellowship Director, Department of Internal Medicine, Division of Adult Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine

Lodovico Balducci, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Physicians, American Geriatrics Society, American Society of Hematology, New York Academy of Sciences, American Society of Clinical Oncology, Southern Society for Clinical Investigation, International Society for Experimental Hematology, American Federation for Clinical Research, American Society of Breast Disease

Disclosure: Nothing to disclose.

Laura Diomede University of Bari School of Medicine, Italy

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Benjamin Movsas, MD 

Benjamin Movsas, MD is a member of the following medical societies: American College of Radiology, American Radium Society, American Society for Radiation Oncology

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Silvia Gagliardi, MD Consulting Staff, Department of Surgery, Medical Center Vita, Italy

Disclosure: Nothing to disclose.

  1. Lancaster E. Paraneoplastic disorders. Continuum (Minneap Minn). 2015 Apr. 21 (2 Neuro-oncology):452-75. [Medline].

  2. Gultekin SH. Recent developments in paraneoplastic disorders of the nervous system. Surg Pathol Clin. 2015 Mar. 8 (1):89-99. [Medline].

  3. Hobbs CB, Miller AL. Review of endocrine syndromes associated with tumours of non-endocrine origin. J Clin Pathol. 1966 Mar. 19(2):119-27. [Medline].

  4. Hashiba T, Saitoh Y, Asanuma N, et al. Reduction of a pancreatic tumor after total removal of an ACTH secreting pituitary tumor: differential diagnosis of Cushing's syndrome. Endocr J. 2006 Apr. 53(2):203-8. [Medline].

  5. Bataller L, Dalmau JO. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Semin Neurol. 2004 Dec. 24(4):461-71. [Medline].

  6. Auche M. Des nevrites peripheriques chez les cancereux. Rev Med. 1890. 10:785-807.

  7. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov. 56(5):715-9. [Medline].

  8. Brain R, Norris FH eds. The remote effects of cancer on the nervous system. New York: Grune & Stratton; 1965.

  9. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol. 2006 Mar. 45(3):251-6. [Medline].

  10. Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012 Oct. 148(10):1165-72. [Medline].

  11. Kawasoe T, Yamamoto Y, Okumura Y, et al. A case report of paraneoplastic neurological syndrome associated with occult breast cancer. Breast Cancer. 2006. 13(2):202-4. [Medline].

  12. Noorani A, Sadiq Z, Minakaran N, et al. Paraneoplastic cerebellar degeneration as a presentation of breast cancer - a case report and review of the literature. Int Semin Surg Oncol. 2008 Apr 21. 5:8. [Medline].

  13. Hagler KT, Lynch JW Jr. Paraneoplastic manifestations of lymphoma. Clin Lymphoma. 2004 Jun. 5(1):29-36. [Medline].

  14. Wiese W, Alansari H, Tranchida P, Madrid FF. Paraneoplastic polyarthritis in an ovarian teratoma. J Rheumatol. 2004 Sep. 31(9):1854-7. [Medline].

  15. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006 Jul. 4(6):631-8. [Medline].

  16. Ge F, Li ZJ, Cao ZL. Thymoma associated with severe diarrhoea and anaemia. Chin Med J (Engl). 2006 Mar 20. 119(6):526-8. [Medline].

  17. Batsis JA, Morgenthaler TI. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc. 2005 Apr. 80(4):537-40. [Medline].

  18. Rabhi M, Ennibi K, Harket A, et al. Acquired ichthyosis disclosing non-Hodgkin's malignant lymphoma. Intern Med. 2007. 46(7):397-9. [Medline].

  19. Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun. 2008. 10:344-58. [Medline].

  20. Molina Garrido MJ, Guillen Ponce C, Macia Escalante S, et al. Cushing's paraneoplastic syndrome as first manifestation of an adenocarcinoma of unknown origin. Clin Transl Oncol. 2006 Aug. 8(8):621-3. [Medline].

  21. Meinardi JR, van den Berg G, Wolffenbuttel BH, et al. Cyclical Cushing's syndrome due to an atypical thymic carcinoid. Neth J Med. 2006 Jan. 64(1):23-7. [Medline].

  22. Takagi J, Otake K, Morishita M, et al. Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. Intern Med. 2006. 45(2):81-6. [Medline].

  23. Mygland A, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000 Apr. 57(4):527-31. [Medline].

  24. Riedel RF, Burfeind WR Jr. Thymoma: benign appearance, malignant potential. Oncologist. 2006 Sep. 11(8):887-94. [Medline].

  25. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008 Jun. 22(3):509-26. [Medline].

  26. Fisher PG, Singer HS. Paraneoplastic opsoclonus. Neurology. 1995 Jul. 45(7):1421-2. [Medline].

  27. Anderson NE. Limbic encephalitis and anti-neuronal antibodies. Pathology. 1989 Apr. 21(2):152-3. [Medline].

  28. Benke T, Wagner M, Pallua AK, et al. Long-term cognitive and MRI findings in a patient with paraneoplastic limbic encephalitis. J Neurooncol. 2003 Jan. 66(1-2):217-24. [Medline].

  29. Cleverly K, Gambadauro P, Navaratnarajah R. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis: have you checked the ovaries?. Acta Obstet Gynecol Scand. 2014 Jul. 93(7):712-5. [Medline].

  30. Rees J. Paraneoplastic neurological disorders. J Neurol Neurosurg Psychiatry. 2014 Aug. 85(8):e3. [Medline].

  31. Ypma PF, Wijermans PW, Koppen H, et al. Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med. 2006 Jul-Aug. 64(7):243-7. [Medline].

  32. Waterhouse DM, Natale RB, Cody RL. Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991 Oct 15. 68(8):1835-41. [Medline].

  33. Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG. Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci. 2010 Jan 18. [Medline].

  34. Scheinfeld NS. Ulcerative paraneoplastic dermatomyositis secondary to metastatic breast cancer. Skinmed. 2006 Mar-Apr. 5(2):94-6. [Medline].

  35. Fardet L, Dupuy A, Gain M, Kettaneh A, Chérin P, Bachelez H, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009 Mar. 88(2):91-7. [Medline].

  36. Marko PB, Miljkovic J, Zemljic TG. Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors. Acta Dermatovenerol Alp Panonica Adriat. 2005 Dec. 14(4):161-4, 166. [Medline].

  37. Savvari P, Peitsidis P, Alevizaki M, Dimopoulos MA, Antsaklis A, Papadimitriou CA. Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: a systematic review. Onkologie. 2009 Sep. 32(8-9):517-23. [Medline].

  38. Fujita T, Fukuda K, Nishi H, et al. Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. Int J Clin Oncol. 2005 Apr. 10(2):144-7. [Medline].

  39. Darnell RB. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol. 2004 Jan. 61(1):30-2. [Medline].

  40. Ubriani R, Grossman ME. Facial papules as a marker of internal malignancy. Med Clin North Am. 2009 Nov. 93(6):1305-31. [Medline].

  41. Iwata T, Inoue K, Mizuguchi S, et al. Thymectomy for paraneoplastic stiff-person syndrome associated with invasive thymoma. J Thorac Cardiovasc Surg. 2006 Jul. 132(1):196-7. [Medline].

  42. Vatankulu B, Yilmaz Aksoy S, Asa S, Sager S, Sayman HB, et al. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Rev Esp Med Nucl Imagen Mol. 2015 Aug 7. [Medline].

  43. Kristensen SB, Hess S, Petersen H, Høilund-Carlsen PF. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. Eur J Nucl Med Mol Imaging. 2015 Jul 21. [Medline].

  44. Buchwald B, Ahangari R, Weishaupt A, et al. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve. 2005 Apr. 31(4):487-94. [Medline].

  45. Koski CL, Patterson JV. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs. 2006 May-Jun. 29(3 Suppl):S21-8. [Medline].

  46. Barnadas M, Roe E, Brunet S, et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol. 2006 Jan. 20(1):69-74. [Medline].

  47. Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004 Jul. 40(6):553-62. [Medline].

  48. Lane JE, Woody C, Davis LS, et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics. 2004 Oct. 114(4):e513-6. [Medline]. [Full Text].

  49. Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol. 2005 Feb. 46(1):1-8; quiz 9-10. [Medline].

  50. Li H, Yan W, Mao Q, et al. Role of adrenalectomy in ectopic ACTH syndrome. Endocr J. 2005 Dec. 52(6):721-6. [Medline].

  51. Akhyani M, Mansoori P, Taheri A, et al. Acrokeratosis paraneoplastica (Bazex syndrome) associated with breast cancer. Clin Exp Dermatol. 2004 Jul. 29(4):429-30. [Medline].

  52. Au WY, Hon C, Chan AC, et al. Vitiligo as a paraneoplastic syndrome preceding pituitary adenoma and subsequent acute lymphoblastic leukemia. Leuk Lymphoma. 2004 Aug. 45(8):1683-5. [Medline].

  53. Chamberlain AJ, Cooper SM, Allen J, et al. Paraneoplastic immunobullous disease with an epidermolysis bullosa acquisita phenotype: two cases demonstrating remission with treatment of gynaecological malignancy. Australas J Dermatol. 2004 May. 45(2):136-9. [Medline].

  54. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006 Mar. 11(3):292-305. [Medline].

  55. Derakhshani P, Klotz T, Heidenreich A, et al. Diffuse metastasized testicular teratoma and paraneoplastic thyreotoxicosis. Case report and literature review. Urol Int. 1999. 63(4):265-7. [Medline].

  56. Dreessen J, Jeanjean AP, Sindic CJ. Paraneoplastic limbic encephalitis: diagnostic relevance of CSF analysis and total body PET scanning. Acta Neurol Belg. 2004 Jun. 104(2):57-63. [Medline].

  57. El Mahou S, Sailler L, Madaule S, et al. RACAND syndrome as a paraneoplastic syndrome?. J Clin Rheumatol. 2006 Apr. 12(2):104-5. [Medline].

  58. Enck RE. Paraneoplastic syndromes. Am J Hosp Palliat Care. 2004 Mar-Apr. 21(2):85-6. [Medline].

  59. Findling JW, Kehoe ME, Raff H. Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent. J Clin Endocrinol Metab. 2004 Dec. 89(12):6005-9. [Medline].

  60. Fong CS. Recent advance in immunological tests in paraneoplastic neurological syndrome. Acta Neurol Taiwan. 2005 Mar. 14(1):28-35. [Medline].

  61. French LE, Piletta PA, Etienne A, et al. Incidence of transient acantholytic dermatosis (Grover's disease) in a hospital setting. Dermatology. 1999. 198(4):410-1. [Medline].

  62. Greenlee JE. Anti-Hu antibody and refractory nonconvulsive status epilepticus. J Neurol Sci. 2006 Jul 15. 246(1-2):1-3. [Medline].

  63. Hermitte L, Martin-Moutot N, Boucraut J, et al. Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome. J Clin Immunol. 2000 Jul. 20(4):287-93. [Medline].

  64. Honnorat J. Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes. Acta Neurol Scand Suppl. 2006. 183:64-8. [Medline].

  65. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007 May 4. 2:22. [Medline].

  66. Honnorat J, Rogemond V, Antoine JC. [Mechanisms of paraneoplastic neurologic syndromes]. Rev Med Interne. 1999 Aug. 20(8):670-80. [Medline].

  67. Iranzo P, Lopez I, Robles MT, et al. Bullous pemphigoid associated with mantle cell lymphoma. Arch Dermatol. 2004 Dec. 140(12):1496-9. [Medline].

  68. Ishibashi H, Akamatsu H, Kojima K, et al. Good syndrome with thymic adenosquamous carcinoma--report of a case. Ann Thorac Cardiovasc Surg. 2007 Feb. 13(1):50-2. [Medline].

  69. Kanno K, Morokuma Y, Tateno T, et al. Olfactory neuroblastoma causing ectopic ACTH syndrome. Endocr J. 2005 Dec. 52(6):675-81. [Medline].

  70. Khachemoune A, Yalamanchili R, Rodriguez C. Bazex syndrome (paraneoplastic acrokeratosis). Cutis. 2004 Nov. 74(5):289-92. [Medline].

  71. Kurzydlo AM, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol. 2004 May. 45(2):130-2. [Medline].

  72. Lecky BR. Transient neonatal Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry. 2006 Sep. 77(9):1094. [Medline].

  73. Lee DH, Lee SH, Sung JK. Inflammatory myofibroblastic tumor on intercostal nerve presenting as paraneoplastic pemphigus with fatal pulmonary involvement. J Korean Med Sci. 2007 Aug. 22(4):735-9. [Medline].

  74. Lee SH, Sung JK. Inflammatory pseudotumor of the spinal nerve complicated by paraneoplastic pemphigus. Case illustration. J Neurosurg Spine. 2006 Jun. 4(6):514. [Medline].

  75. Leidinger B, Bielack S, Koehler G, et al. High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature. J Cancer Res Clin Oncol. 2004 Jun. 130(6):357-61. [Medline].

  76. Lladó A, Carpentier AF, Honnorat J, et al. Hu-antibody-positive patients with or without cancer have similar clinicalprofiles. J Neurol Neurosurg Psychiatry. 2006 Aug. 77(8):996-7. [Medline].

  77. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg [Am]. 2004 Jul. 29(4):654-60. [Medline].

  78. Mayer S, Cypess AM, Kocher ON, et al. Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol. 2005 Feb 20. 23(6):1312-4. [Medline].

  79. Menenakos C, Braumann C, Hartmann J, et al. Retroperitoneal Castleman's tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J Surg Oncol. 2007 Apr 28. 5:45. [Medline].

  80. Morita H, Hirota T, Mune T, et al. Paraneoplastic neurologic syndrome and autoimmune Addison disease in a patient with thymoma. Am J Med Sci. 2005 Jan. 329(1):48-51. [Medline].

  81. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006 Feb. 7(2):169-75. [Medline].

  82. Noda M, Mori N, Nomura K, et al. Regression of idiopathic thrombocytopenic purpura after endoscopic mucosal resection of gastric mucosa associated lymphoid tissue lymphoma. Gut. 2004 Nov. 53(11):1698-700. [Medline].

  83. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004 Nov. 240(5):757-73. [Medline].

  84. Ono H, Yokozeki H, Katayama I, et al. Granuloma annulare in a patient with malignant lymphoma. Dermatology. 1997. 195(1):46-7. [Medline].

  85. Perez NB, Bernad B, Narvaez J, et al. Erythema nodosum and lung cancer. Joint Bone Spine. 2006 May. 73(3):336-7. [Medline].

  86. Peter L, Jung J, Tilikete C, Ryvlin P, Mauguiere F. Opsoclonus-myoclonus as a manifestation of Lyme disease. J Neurol Neurosurg Psychiatry. 2006 Sep. 77(9):1090-1. [Medline].

  87. Pittock SJ, Lucchinetti CF. Inflammatory transverse myelitis: evolving concepts. Curr Opin Neurol. 2006 Aug. 19(4):362-8. [Medline].

  88. Posner JB. 10 Most Commonly Asked Questions About Paraneoplastic Syndromes. The Neurologist. 1998. [Full Text].

  89. Rosenzweig LB, Brett AS, Lefaivre JF, et al. Hidradenitis suppurativa complicated by squamous cell carcinoma and paraneoplastic neuropathy. Am J Med Sci. 2005 Mar. 329(3):150-2. [Medline].

  90. Shimoda T, Koizumi W, Tanabe S, et al. Small-cell carcinoma of the esophagus associated with a paraneoplastic neurological syndrome: a case report documenting a complete response. Jpn J Clin Oncol. 2006 Feb. 36(2):109-12. [Medline].

  91. Simpson DA, Pawlak AM, Tegmeyer L, Doig C, Cox D. Paraneoplastic intestinal pseudo-obstruction, mononeuritis multiplex, and sensoryneuropathy/neuronopathy. J Am Osteopath Assoc. 1996. 96(2):125-8. [Medline].

  92. Sökmen M, Demirsoy H, Ersoy O, et al. Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: Casereport. Turk J Gastroenterol. 2007. 18(3):200-205. [Medline].

  93. Tartaglia F, Blasi S, Sgueglia M, Polichetti P, Tromba L, Berni A. Retroperitoneal liposarcoma associated with small plaque parapsoriasis. World J Surg Oncol. 2007 Jul. 5:76. [Medline].

  94. Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol. 2004 Feb. 5(1):51-62. [Medline].

  95. Torgerson EL, Khalili R, Dobkin BH, et al. Myasthenia gravis as a paraneoplastic syndrome associated with renal cell carcinoma. J Urol. 1999 Jul. 162(1):154. [Medline].

  96. Tsuchiya K, Minami I, Tateno T, et al. Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays. Endocr J. 2005 Dec. 52(6):743-50. [Medline].

  97. Waldum H. Assessment of the risk of iatrogenic hypergastrinaemia from patients with gastrinoma. Basic Clin Pharmacol Toxicol. 2006 Jan. 98(1):3. [Medline].

  98. Wilson J. Neuroimmunology of dancing eye syndrome in children. Dev Med Child Neurol. 2006 Aug. 48(8):693-6. [Medline].

  99. Bilynsky BT, Dzhus MB, Litvinyak RI. The conceptual and clinical problems of paraneoplastic syndrome in oncology and internal medicine. Exp Oncol. 2015 Jun. 37 (2):82-8. [Medline].

  100. Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015 Sep 1. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.